| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA4478731 | F | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human red blood cells assessed as parasite growth inhibition by SYBR assay | Plasmodium falciparum | 47 | organism-based format | Scientific Literature | ||
| 2. | ALA4478732 | A | Cytotoxicity against human MRC5 cells after 68 hrs by resazurin assay | Homo sapiens | 47 | cell-based format | Scientific Literature | ||
| 3. | ALA4478733 | A | Intrinsic clearance in CD1 mouse liver microsomes at 0.5 uM after 3 to 30 mins in presence of NADPH by UPLC/MS/MS analysis | Mus musculus | 11 | microsome format | Scientific Literature | ||
| 4. | ALA4478734 | P | Aqueous kinetic solubility of the compound in water at 5 to 100 ug/mL by laser nephelometric analysis | 11 | small-molecule physicochemical format | Scientific Literature | |||
| 5. | ALA4478735 | F | Antimalarial activity against chloroquine/pyrimethamine-sensitive Plasmodium falciparum K1 infected in human red blood cells assessed as parasite growth inhibition by SYBR assay | Plasmodium falciparum | 2 | organism-based format | Scientific Literature | ||
| 6. | ALA4478736 | A | Protein binding in CD1 mouse plasma at 10 ug/mL after 5 hrs by UPLC-MS/MS analysis based equilibrium dialysis method | Mus musculus | 3 | cell-free format | Scientific Literature | ||
| 7. | ALA4478737 | A | Inhibition of human CYP1A2 expressed in Escherichia coli pre-incubated for 5 mins before regenerating cofactor solution addition using Ethoxyresorufin as substrate by fluorescence assay | Homo sapiens | 10 | assay format | Scientific Literature | ||
| 8. | ALA4478738 | A | Inhibition of human CYP2C9 expressed in Escherichia coli pre-incubated for 5 mins before regenerating cofactor solution addition using 7-methoxy-4-(trifluoromethyl)-coumarin as substrate by fluorescence assay | Homo sapiens | 10 | assay format | Scientific Literature | ||
| 9. | ALA4478739 | A | Inhibition of human CYP2C19 expressed in Escherichia coli pre-incubated for 5 mins before regenerating cofactor solution addition using 3-Cyano-7-Ethoxycoumarin as substrate by fluorescence assay | Homo sapiens | 10 | assay format | Scientific Literature | ||
| 10. | ALA4478740 | A | Inhibition of human CYP2D6 expressed in Escherichia coli pre-incubated for 5 mins before regenerating cofactor solution addition using 7-methoxy-4-(aminomethyl)-coumarin as substrate by fluorescence assay | Homo sapiens | 10 | assay format | Scientific Literature | ||
| 11. | ALA4478741 | A | Inhibition of human CYP3A4 expressed in Escherichia coli pre-incubated for 5 mins before regenerating cofactor solution addition using Diethoxyfluorescein/7-Benzyloxyquinoline as substrate by fluorescence assay | Homo sapiens | 11 | assay format | Scientific Literature | ||
| 12. | ALA4478742 | B | Inhibition of human ERG by patch clamp assay | Homo sapiens | 2 | assay format | Scientific Literature | ||
| 13. | ALA4478751 | F | In vivo antimalarial activity against Plasmodium falciparum 3D70087/N9-infected erythrocytes engrafted in NOD-scid IL-2Ryc-null mouse assessed as reduction in parasitaemia administered qd through oral gavage for 4 days measured after 7 days by SYTO-16/TER119 monoclonal antibody-based flow cytometric analysis | Plasmodium falciparum | 1 | organism-based format | Scientific Literature | ||
| 14. | ALA4478752 | F | In vivo antimalarial activity against Plasmodium falciparum 3D70087/N9-infected erythrocytes engrafted in NOD-scid IL-2Ryc-null mouse assessed as reduction in parasitaemia at >/= 20 mg/kg administered qd through oral gavage for 4 days measured after 2 days by SYTO-16/TER119 monoclonal antibody-based flow cytometric analysis | Plasmodium falciparum | 1 | organism-based format | Scientific Literature | ||
| 15. | ALA4478753 | F | In vivo antimalarial activity against Plasmodium falciparum 3D70087/N9-infected erythrocytes engrafted in NOD-scid IL-2Ryc-null mouse assessed as reduction in parasitaemia at >/= 30 mg/kg administered qd through oral gavage for 4 days measured after 2 days by SYTO-16/TER119 monoclonal antibody-based flow cytometric analysis | Plasmodium falciparum | 1 | organism-based format | Scientific Literature | ||
| 16. | ALA4478754 | F | In vivo antimalarial activity against Plasmodium falciparum 3D70087/N9-infected erythrocytes engrafted in NOD-scid IL-2Ryc-null mouse assessed as concentration required to reduce parasitaemia by 90 % administered qd through oral gavage for 4 days measured after 7 days by SYTO-16/TER119 monoclonal antibody-based flow cytometric analysis | Plasmodium falciparum | 1 | organism-based format | Scientific Literature | ||
| 17. | ALA4478755 | F | Antimalarial activity against Plasmodium falciparum infected in mouse peripheral blood assessed as pyknotic parasites at 100 mg/kg after 48 hrs by serial dilution analysis | Plasmodium falciparum | 1 | organism-based format | Scientific Literature | ||
| 18. | ALA4478756 | F | Antimalarial activity against Plasmodium falciparum using fresh erythrocytes and renewed compound addition daily over entire treatment period assessed as parasite reduction ratio at 10 times EC50 after 52 hrs by serial dilution analysis relative to control | Plasmodium falciparum | 1 | organism-based format | Scientific Literature | ||
| 19. | ALA4478757 | U | Inhibition of beta-haematin formation after 12 to 14 hrs by microplate assay | 2 | assay format | Scientific Literature | |||
| 20. | ALA4478758 | F | Antimalarial activity against Plasmodium falciparum K1 assessed as inhibition of beta-haematin formation after 12 to 14 hrs by microplate assay | Plasmodium falciparum | 1 | organism-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!